2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure

Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD

Grade Working Group. The Grading of Recommendations Assessment, Development and Evaluation (GRADE). 2016. Available at: www.gradeworkinggroup.org. Accessed February 16, 2016.

Hunt, 2001, Circulation, 104, 2996, 10.1161/hc4901.102568

Arbustini, 2013, The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation, J Am Coll Cardiol, 62, 2046, 10.1016/j.jacc.2013.08.1644

Kalogeropoulos, 2016, Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction, JAMA Cardiol, 1, 510, 10.1001/jamacardio.2016.1325

1994

Levy, 2006, The Seattle Heart Failure Model: prediction of survival in heart failure, Circulation, 113, 1424, 10.1161/CIRCULATIONAHA.105.584102

Pocock, 2013, Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies, Eur Heart J, 34, 1404, 10.1093/eurheartj/ehs337

Senni, 2013, Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score, Int J Cardiol, 163, 206, 10.1016/j.ijcard.2011.10.071

Lupon, 2014, Development of a novel heart failure risk tool: the barcelona bio-heart failure risk calculator (BCN bio-HF calculator), PLoS One, 9, e85466, 10.1371/journal.pone.0085466

Lee, 2003, Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model, JAMA, 290, 2581, 10.1001/jama.290.19.2581

Lee, 2012, Prediction of heart failure mortality in emergent care: a cohort study, Ann Intern Med, 156, 767, 10.7326/0003-4819-156-11-201206050-00003

Salah, 2014, A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score, Heart, 100, 115, 10.1136/heartjnl-2013-303632

Fonarow, 2005, Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis, JAMA, 293, 572, 10.1001/jama.293.5.572

van Walraven, 2010, Derivation and validation of an index to predict early death or unplanned readmission after discharge from hospital to the community, CMAJ, 182, 551, 10.1503/cmaj.091117

Wang, 2003, Natural history of asymptomatic left ventricular systolic dysfunction in the community, Circulation, 108, 977, 10.1161/01.CIR.0000085166.44904.79

Ledwidge, 2013, Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial, JAMA, 310, 66, 10.1001/jama.2013.7588

Huelsmann, 2013, PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial, J Am Coll Cardiol, 62, 1365, 10.1016/j.jacc.2013.05.069

Pandey, 2015, Dose-response relationship between physical activity and risk of heart failure: a meta-analysis, Circulation, 132, 1786, 10.1161/CIRCULATIONAHA.115.015853

Eriksson, 1989, Risk factors for heart failure in the general population: the study of men born in 1913, Eur Heart J, 10, 647, 10.1093/oxfordjournals.eurheartj.a059542

Ho, 1993, The epidemiology of heart failure: the Framingham Study, J Am Coll Cardiol, 22, 6A, 10.1016/0735-1097(93)90455-A

Nicklas, 2006, Abdominal obesity is an independent risk factor for chronic heart failure in older people, J Am Geriatr Soc, 54, 413, 10.1111/j.1532-5415.2005.00624.x

Kenchaiah, 2004, Impact of obesity on the risk of heart failure and survival after the onset of heart failure, Med Clin North Am, 88, 1273, 10.1016/j.mcna.2004.04.011

Kenchaiah, 2002, Obesity and the risk of heart failure, N Engl J Med, 347, 305, 10.1056/NEJMoa020245

Aune, 2016, Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies, Circulation, 133, 639, 10.1161/CIRCULATIONAHA.115.016801

Baena-Diez, 2010, Obesity is an independent risk factor for heart failure: Zona Franca Cohort study, Clin Cardiol, 33, 760, 10.1002/clc.20837

Fitchett, 2016, Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial, Eur Heart J, 37, 1526, 10.1093/eurheartj/ehv728

Levy, 1996, The progression from hypertension to congestive heart failure, JAMA, 275, 1557, 10.1001/jama.1996.03530440037034

Bell, 2003, Heart failure: the frequent, forgotten, and often fatal complication of diabetes, Diabetes Care, 26, 2433, 10.2337/diacare.26.8.2433

Turnbull, 2003, Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials, Lancet, 362, 1527, 10.1016/S0140-6736(03)14739-3

Williamson, 2016, Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial, JAMA, 315, 2673, 10.1001/jama.2016.7050

Kannel, 1974, Role of diabetes in congestive heart failure: the Framingham study, Am J Cardiol, 34, 29, 10.1016/0002-9149(74)90089-7

He, 2001, Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study, Arch Intern Med, 161, 996, 10.1001/archinte.161.7.996

Sharma, 2014, Diabetes, impaired fasting glucose, and heart failure: it's not all about the sugar, Eur J Heart Fail, 16, 1153, 10.1002/ejhf.179

Nichols, 2004, The incidence of congestive heart failure in type 2 diabetes: an update, Diabetes Care, 27, 1879, 10.2337/diacare.27.8.1879

Thrainsdottir, 2005, The association between glucose abnormalities and heart failure in the population-based Reykjavik study, Diabetes Care, 28, 612, 10.2337/diacare.28.3.612

Bertoni, 2004, Heart failure prevalence, incidence, and mortality in the elderly with diabetes, Diabetes Care, 27, 699, 10.2337/diacare.27.3.699

Johansson, 2001, Incidence of newly diagnosed heart failure in UK general practice, Eur J Heart Fail, 3, 225, 10.1016/S1388-9842(00)00131-8

1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401

1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6

Holman, 2008, 10-Year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med, 359, 1577, 10.1056/NEJMoa0806470

Gerstein, 2008, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545, 10.1056/NEJMoa0802743

Group, 2011, Long-term effects of intensive glucose lowering on cardiovascular outcomes, N Engl J Med, 364, 818, 10.1056/NEJMoa1006524

Group, 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med, 358, 2560, 10.1056/NEJMoa0802987

Duckworth, 2009, Glucose control and vascular complications in veterans with type 2 diabetes, N Engl J Med, 360, 129, 10.1056/NEJMoa0808431

MacDonald, 2010, Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database, Diabetes Care, 33, 1213, 10.2337/dc09-2227

Zinman, 2015, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, 373, 2117, 10.1056/NEJMoa1504720

Scirica, 2013, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, N Engl J Med, 369, 1317, 10.1056/NEJMoa1307684

Green, 2015, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes, N Engl J Med, 373, 232, 10.1056/NEJMoa1501352

Zannad, 2015, Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial, Lancet, 385, 2067, 10.1016/S0140-6736(14)62225-X

Rosenstock, 2015, Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events, Cardiovasc Diabetol, 14, 57, 10.1186/s12933-015-0215-2

Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med, 375, 311, 10.1056/NEJMoa1603827

Erdmann, 2007, Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08), Diabetes Care, 30, 2773, 10.2337/dc07-0717

Komajda, 2010, Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial, Eur Heart J, 31, 824, 10.1093/eurheartj/ehp604

Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med, 356, 2457, 10.1056/NEJMoa072761

Virani, 2016, Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy, Can J Cardiol, 32, 831, 10.1016/j.cjca.2016.02.078

Moe, 2005, BNP in the diagnosis and risk stratification of heart failure, Heart Fail Monit, 4, 116

Ahmad, 2014, Charting a roadmap for heart failure biomarker studies, JACC Heart Fail, 2, 477, 10.1016/j.jchf.2014.02.005

Burke, 2007, Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions, Heart Fail Rev, 12, 23, 10.1007/s10741-007-9002-9

Thygesen, 2012, Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care, Eur Heart J, 33, 2001, 10.1093/eurheartj/ehq509

Daniels, 2006, How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study, Am Heart J, 151, 999, 10.1016/j.ahj.2005.10.011

Moe, 2015, The 2014 Canadian Cardiovascular Society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications, Can J Cardiol, 31, 3, 10.1016/j.cjca.2014.10.022

Ponikowski, 2016, Eur J Heart Fail, 18, 891, 10.1002/ejhf.592

Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 128, e240, 10.1161/CIR.0b013e31829e8807

van Veldhuisen, 2013, B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction, J Am Coll Cardiol, 61, 1498, 10.1016/j.jacc.2012.12.044

Sepehrvand, 2016, Factors associated with natriuretic peptide testing in patients presenting to emergency departments with suspected heart failure, Can J Cardiol, 32, 986.e1, 10.1016/j.cjca.2015.11.019

Troughton, 2014, Natriuretic peptide-guided heart failure management, Eur Heart J, 35, 16, 10.1093/eurheartj/eht463

Masson, 2006, Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data, Clin Chem, 52, 1528, 10.1373/clinchem.2006.069575

Doust, 2005, How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review, BMJ, 330, 625, 10.1136/bmj.330.7492.625

Cleland, 2009, J Am Coll Cardiol, 54, 1850, 10.1016/j.jacc.2009.06.041

Berger, 2010, N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study, J Am Coll Cardiol, 55, 645, 10.1016/j.jacc.2009.08.078

Sanders-van Wijk, 2013, Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF, Eur J Heart Fail, 15, 910, 10.1093/eurjhf/hft079

Motiwala, 2013, The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure, Clin Pharmacol Ther, 93, 57, 10.1038/clpt.2012.187

Stienen, 2014, Rationale and design of PRIMA II: a multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a predefined NT-PRoBNP target on the reduction of readmIssion and Mortality rAtes, Am Heart J, 168, 30, 10.1016/j.ahj.2014.04.008

Felker, 2014, Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure, JACC Heart Fail, 2, 457, 10.1016/j.jchf.2014.05.007

Cleland, 2008, Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial, J Am Coll Cardiol, 52, 438, 10.1016/j.jacc.2008.04.036

Shanmugam, 2013, Effect of atrioventricular optimization on circulating N-terminal pro brain natriuretic peptide following cardiac resynchronization therapy, Eur J Heart Fail, 15, 534, 10.1093/eurjhf/hft012

Davis, 2006, Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure, Circulation, 113, 977, 10.1161/CIRCULATIONAHA.105.567727

Packer, 2015, Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure, Circulation, 131, 54, 10.1161/CIRCULATIONAHA.114.013748

Paulus, 2007, How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology, Eur Heart J, 28, 2539, 10.1093/eurheartj/ehm037

Jeevanantham, 2007, Elevated B-type natriuretic peptide level: use with caution in patients with multiple co-morbidities and presenting with dyspnea, Indian Heart J, 59, 64

Carlsen, 2012, Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study, Eur J Heart Fail, 14, 240, 10.1093/eurjhf/hfs003

Cleland, 2012, Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study, Eur J Heart Fail, 14, 487, 10.1093/eurjhf/hfs049

Anand, 2011, Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial, Circ Heart Fail, 4, 569, 10.1161/CIRCHEARTFAILURE.111.962654

Pfeffer, 2015, Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial, Circulation, 131, 34, 10.1161/CIRCULATIONAHA.114.013255

Ibrahim, 2016, Established and emerging roles of biomarkers in heart failure clinical trials, Circ Heart Fail, 9, e002528, 10.1161/CIRCHEARTFAILURE.115.002528

Latini, 2007, Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure, Circulation, 116, 1242, 10.1161/CIRCULATIONAHA.106.655076

Kociol, 2010, Troponin elevation in heart failure prevalence, mechanisms, and clinical implications, J Am Coll Cardiol, 56, 1071, 10.1016/j.jacc.2010.06.016

Pascual-Figal, 2011, Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure, Eur J Heart Fail, 13, 718, 10.1093/eurjhf/hfr047

Masson, 2012, Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials, Circulation, 125, 280, 10.1161/CIRCULATIONAHA.111.044149

Santhanakrishnan, 2012, Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction, Eur J Heart Fail, 14, 1338, 10.1093/eurjhf/hfs130

Peacock, 2008, Cardiac troponin and outcome in acute heart failure, N Engl J Med, 358, 2117, 10.1056/NEJMoa0706824

Pfeffer, 1992, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators, N Engl J Med, 327, 669, 10.1056/NEJM199209033271001

1987, Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group, N Engl J Med, 316, 1429

Kober, 1995, A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group, N Engl J Med, 333, 1670, 10.1056/NEJM199512213332503

Yusuf, 1991, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501

Garg, 1995, Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials, JAMA, 273, 1450, 10.1001/jama.1995.03520420066040

Yusuf, 1992, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions, N Engl J Med, 327, 685, 10.1056/NEJM199209033271003

1993, Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators, Lancet, 342, 821

Shibata, 2001, Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure, Eur J Heart Fail, 3, 351, 10.1016/S1388-9842(01)00144-1

Dargie, 2001, Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial, Lancet, 357, 1385, 10.1016/S0140-6736(00)04560-8

1999, Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2

1999, The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet, 353, 9, 10.1016/S0140-6736(98)11181-9

Packer, 2001, Effect of carvedilol on survival in severe chronic heart failure, N Engl J Med, 344, 1651, 10.1056/NEJM200105313442201

Pfeffer, 2003, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both, N Engl J Med, 349, 1893, 10.1056/NEJMoa032292

Cohn, 2001, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med, 345, 1667, 10.1056/NEJMoa010713

Granger, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial, Lancet, 362, 772, 10.1016/S0140-6736(03)14284-5

Lee, 2004, Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction, Ann Intern Med, 141, 693, 10.7326/0003-4819-141-9-200411020-00011

Ezekowitz, 2009, Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials, Eur Heart J, 30, 469, 10.1093/eurheartj/ehn543

Zannad, 2011, Eplerenone in patients with systolic heart failure and mild symptoms, N Engl J Med, 364, 11, 10.1056/NEJMoa1009492

Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001

Flather, 2000, Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group, Lancet, 355, 1575, 10.1016/S0140-6736(00)02212-1

Shekelle, 2003, Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials, J Am Coll Cardiol, 41, 1529, 10.1016/S0735-1097(03)00262-6

McMurray, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial, Lancet, 362, 767, 10.1016/S0140-6736(03)14283-3

Lakhdar, 2008, J Card Fail, 14, 181, 10.1016/j.cardfail.2007.11.008

Packer, 1996, The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group, N Engl J Med, 334, 1349, 10.1056/NEJM199605233342101

Hjalmarson, 2000, Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group, JAMA, 283, 1295, 10.1001/jama.283.10.1295

Packer, 2002, Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study, Circulation, 106, 2194, 10.1161/01.CIR.0000035653.72855.BF

Bristow, 1996, Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators, Circulation, 94, 2807, 10.1161/01.CIR.94.11.2807

1997, Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group, Lancet, 349, 375, 10.1016/S0140-6736(97)80008-6

1994, A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees, Circulation, 90, 1765, 10.1161/01.CIR.90.4.1765

Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 348, 1309, 10.1056/NEJMoa030207

Maric, 2006, Interactions between angiotensin II and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase, Nephron Physiol, 103, p149, 10.1159/000092457

Cruden, 2004, Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition, Hypertension, 44, 913, 10.1161/01.HYP.0000146483.78994.56

McMurray, 2014, Angiotensin-neprilysin inhibition versus enalapril in heart failure, N Engl J Med, 371, 993, 10.1056/NEJMoa1409077

Diaz, 2005, Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease, Eur Heart J, 26, 967, 10.1093/eurheartj/ehi190

Fox, 2008, Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial, Lancet, 372, 817, 10.1016/S0140-6736(08)61171-X

McAlister, 2009, Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure, Ann Intern Med, 150, 784, 10.7326/0003-4819-150-11-200906020-00006

Komajda, 2009, Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II, Eur Heart J, 30, 478, 10.1093/eurheartj/ehn539

Flannery, 2008, Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers, Am J Cardiol, 101, 865, 10.1016/j.amjcard.2007.11.023

Komajda, 2003, The EuroHeart Failure Survey programme–a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment, Eur Heart J, 24, 464, 10.1016/S0195-668X(02)00700-5

DiFrancesco, 2007, The funny current: cellular basis for the control of heart rate, Drugs, 67, 15, 10.2165/00003495-200767002-00003

Colin, 2003, Contributions of heart rate and contractility to myocardial oxygen balance during exercise, Am J Physiol Heart Circ Physiol, 284, H676, 10.1152/ajpheart.00564.2002

Fox, 2008, Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 807, 10.1016/S0140-6736(08)61170-8

Swedberg, 2010, Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study, Lancet, 376, 875, 10.1016/S0140-6736(10)61198-1

Cohn, 1986, Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study, N Engl J Med, 314, 1547, 10.1056/NEJM198606123142404

Cohn, 1991, A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure, N Engl J Med, 325, 303, 10.1056/NEJM199108013250502

Taylor, 2004, Combination of isosorbide dinitrate and hydralazine in blacks with heart failure, N Engl J Med, 351, 2049, 10.1056/NEJMoa042934

1997, The effect of digoxin on mortality and morbidity in patients with heart failure, N Engl J Med, 336, 525, 10.1056/NEJM199702203360801

Hood, 2014, Digitalis for treatment of heart failure in patients in sinus rhythm, Cochrane Database Syst Rev, CD002901

Tavazzi, 2008, Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1223, 10.1016/S0140-6736(08)61239-8

Tatarczyk, 2007, Analysis of long-chain omega-3 fatty acid content in fish-oil supplements, Wien Klin Wochenschr, 119, 417, 10.1007/s00508-007-0820-5

Villani, 2013, Fish oil administration in older adults: is there potential for adverse events? A systematic review of the literature, BMC Geriatr, 13, 41, 10.1186/1471-2318-13-41

Kris-Etherton, 2008, N-3 fatty acids: food or supplements?, J Am Diet Assoc, 108, 1125, 10.1016/j.jada.2008.04.025

Kjekshus, 2007, Rosuvastatin in older patients with systolic heart failure, N Engl J Med, 357, 2248, 10.1056/NEJMoa0706201

van der Harst, 2006, Statins in the treatment of chronic heart failure: a systematic review, PLoS Med, 3, e333, 10.1371/journal.pmed.0030333

Tavazzi, 2008, Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1231, 10.1016/S0140-6736(08)61240-4

Baigent, 2009, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Lancet, 373, 1849, 10.1016/S0140-6736(09)60503-1

Massie, 2009, Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial, Circulation, 119, 1616, 10.1161/CIRCULATIONAHA.108.801753

Homma, 2012, Warfarin and aspirin in patients with heart failure and sinus rhythm, N Engl J Med, 366, 1859, 10.1056/NEJMoa1202299

Hopper, 2013, Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythm, Eur J Heart Fail, 15, 69, 10.1093/eurjhf/hfs171

Kumar, 2013, Warfarin versus aspirin for prevention of stroke in heart failure: a meta-analysis of randomized controlled clinical trials, J Stroke Cerebrovasc Dis, 22, 1279, 10.1016/j.jstrokecerebrovasdis.2012.09.015

Solheim, 2010, Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy, Am J Cardiol, 106, 1197, 10.1016/j.amjcard.2010.06.043

Nikolsky, 2012, Am J Cardiol, 109, 831, 10.1016/j.amjcard.2011.10.046

Schwalm, 2010, Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial, J Thromb Thrombolysis, 30, 127, 10.1007/s11239-010-0448-6

Le May, 2015, Prophylactic warfarin therapy after primary percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction, JACC Cardiovasc Interv, 8, 155, 10.1016/j.jcin.2014.07.018

Udell, 2010, Anticoagulation after anterior myocardial infarction and the risk of stroke, PLoS One, 5, e12150, 10.1371/journal.pone.0012150

Page, 2000, Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem, Arch Intern Med, 160, 777, 10.1001/archinte.160.6.777

Heerdink, 1998, NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics, Arch Intern Med, 158, 1108, 10.1001/archinte.158.10.1108

Mamdani, 2004, Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study, Lancet, 363, 1751, 10.1016/S0140-6736(04)16299-5

Gislason, 2009, Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure, Arch Intern Med, 169, 141, 10.1001/archinternmed.2008.525

Hudson, 2005, Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study, BMJ, 330, 1370, 10.1136/bmj.330.7504.1370

Feenstra, 2002, Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study, Arch Intern Med, 162, 265, 10.1001/archinte.162.3.265

Elkayam, 1990, A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure, Circulation, 82, 1954, 10.1161/01.CIR.82.6.1954

Littler, 1995, Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group, Br Heart J, 73, 428, 10.1136/hrt.73.5.428

Goldstein, 1991, Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group, Circulation, 83, 52, 10.1161/01.CIR.83.1.52

1990, Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II), Am J Cardiol, 66, 779, 10.1016/0002-9149(90)90351-Z

Packer, 1996, Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group, N Engl J Med, 335, 1107, 10.1056/NEJM199610103351504

Packer, 2013, Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2), JACC Heart Fail, 1, 308, 10.1016/j.jchf.2013.04.004

Yusuf, 2003, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial, Lancet, 362, 777, 10.1016/S0140-6736(03)14285-7

Rogers, 2014, Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved, Eur J Heart Fail, 16, 33, 10.1002/ejhf.29

Cleland, 2006, The perindopril in elderly people with chronic heart failure (PEP-CHF) study, Eur Heart J, 27, 2338, 10.1093/eurheartj/ehl250

Massie, 2008, Irbesartan in patients with heart failure and preserved ejection fraction, N Engl J Med, 359, 2456, 10.1056/NEJMoa0805450

Pitt, 2014, Spironolactone for heart failure with preserved ejection fraction, N Engl J Med, 370, 1383, 10.1056/NEJMoa1313731

De Denus, 2017, Spironolactone metabolites in TOPCAT: new insights into regional variations, N Engl J Med, 376, 1690, 10.1056/NEJMc1612601

Bavishi, 2015, Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis, Heart Fail Rev, 20, 193, 10.1007/s10741-014-9453-8

Liu, 2014, Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis, PLoS One, 9, e90555, 10.1371/journal.pone.0090555

Flather, 2005, Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS), Eur Heart J, 26, 215, 10.1093/eurheartj/ehi115

Yamamoto, 2013, Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF), Eur J Heart Fail, 15, 110, 10.1093/eurjhf/hfs141

van Veldhuisen, 2009, Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure), J Am Coll Cardiol, 53, 2150, 10.1016/j.jacc.2009.02.046

Redfield, 2015, Isosorbide mononitrate in heart failure with preserved ejection fraction, N Engl J Med, 373, 2314, 10.1056/NEJMoa1510774

Arnold, 2006, Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management, Can J Cardiol, 22, 23, 10.1016/S0828-282X(06)70237-9

Howlett, 2009, Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials, Can J Cardiol, 25, 85, 10.1016/S0828-282X(09)70477-5

McKelvie, 2013, The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure, Can J Cardiol, 29, 168, 10.1016/j.cjca.2012.10.007

Connolly, 2000, Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone, Circulation, 101, 1297, 10.1161/01.CIR.101.11.1297

1997, A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias, N Engl J Med, 337, 1576, 10.1056/NEJM199711273372202

Kuck, 2000, Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH), Circulation, 102, 748, 10.1161/01.CIR.102.7.748

Connolly, 2000, Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study, Eur Heart J, 21, 2071, 10.1053/euhj.2000.2476

Bardy, 2005, Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure, N Engl J Med, 352, 225, 10.1056/NEJMoa043399

Moss, 2002, Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction, N Engl J Med, 346, 877, 10.1056/NEJMoa013474

Hohnloser, 2004, Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction, N Engl J Med, 351, 2481, 10.1056/NEJMoa041489

Steinbeck, 2009, Defibrillator implantation early after myocardial infarction, N Engl J Med, 361, 1427, 10.1056/NEJMoa0901889

Ezekowitz, 2007, Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction, Ann Intern Med, 147, 251, 10.7326/0003-4819-147-4-200708210-00007

Kadish, 2004, Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy, N Engl J Med, 350, 2151, 10.1056/NEJMoa033088

Kober, 2016, Defibrillator implantation in patients with nonischemic systolic heart failure, N Engl J Med, 375, 1221, 10.1056/NEJMoa1608029

Golwala, 2017, Implantable cardioverter-defibrillator for nonischemic cardiomyopathy: an updated meta-analysis, Circulation, 135, 201, 10.1161/CIRCULATIONAHA.116.026056

Bennett, 2017, Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 implantable cardioverter-defibrillator guidelines, Can J Cardiol, 33, 174, 10.1016/j.cjca.2016.09.009

Exner, 2013, Canadian Cardiovascular Society guidelines on the use of cardiac resynchronization therapy: evidence and patient selection, Can J Cardiol, 29, 182, 10.1016/j.cjca.2012.10.006

Bigger, 1999, Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery, Circulation, 99, 1416, 10.1161/01.CIR.99.11.1416

Goldenberg, 2006, Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II, J Am Coll Cardiol, 47, 1811, 10.1016/j.jacc.2005.12.048

Barsheshet, 2011, Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial, J Cardiovasc Electrophysiol, 22, 1237, 10.1111/j.1540-8167.2011.02096.x

Bax, 2004, Extensive left ventricular remodeling does not allow viable myocardium to improve in left ventricular ejection fraction after revascularization and is associated with worse long-term prognosis, Circulation, 110, II18, 10.1161/01.CIR.0000138195.33452.b0

Bristow, 2004, Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure, N Engl J Med, 350, 2140, 10.1056/NEJMoa032423

Cleland, 2005, The effect of cardiac resynchronization on morbidity and mortality in heart failure, N Engl J Med, 352, 1539, 10.1056/NEJMoa050496

Tang, 2010, Cardiac-resynchronization therapy for mild-to-moderate heart failure, N Engl J Med, 363, 2385, 10.1056/NEJMoa1009540

Leon, 2005, Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: combined results of over 2,000 patients from a multicenter study program, J Am Coll Cardiol, 46, 2348, 10.1016/j.jacc.2005.08.031

Ailawadi, 2010, Surgically placed left ventricular leads provide similar outcomes to percutaneous leads in patients with failed coronary sinus lead placement, Heart Rhythm, 7, 619, 10.1016/j.hrthm.2010.01.014

Penicka, 2007, Severe left ventricular dyssynchrony is associated with poor prognosis in patients with moderate systolic heart failure undergoing coronary artery bypass grafting, J Am Coll Cardiol, 50, 1315, 10.1016/j.jacc.2007.03.070

Pokushalov, 2010, Coronary artery bypass grafting with concomitant cardiac resynchronisation therapy in patients with ischaemic heart failure and left ventricular dyssynchrony, Eur J Cardiothorac Surg, 38, 773, 10.1016/j.ejcts.2010.03.036

Healey, 2012, Canadian Cardiovascular Society/Canadian Anesthesiologists' Society/Canadian Heart Rhythm Society joint position statement on the perioperative management of patients with implanted pacemakers, defibrillators, and neurostimulating devices, Can J Cardiol, 28, 141, 10.1016/j.cjca.2011.08.121

Gersh, 2011, J Am Coll Cardiol, 58, e212, 10.1016/j.jacc.2011.06.011

Elliott, 2014, 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284

O'Mahony, 2013, Heart, 99, 534, 10.1136/heartjnl-2012-303271

O'Mahony, 2014, A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD), Eur Heart J, 35, 2010, 10.1093/eurheartj/eht439

Maron, 2015, Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy, Am J Cardiol, 116, 757, 10.1016/j.amjcard.2015.05.047

Vriesendorp, 2015, Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy, Circ Arrhythm Electrophysiol, 8, 829, 10.1161/CIRCEP.114.002553

Al-Majed, 2011, Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure, Ann Intern Med, 154, 401, 10.7326/0003-4819-154-6-201103150-00313

Wells, 2011, Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials, CMAJ, 183, 421, 10.1503/cmaj.101685

Chen, 2013, The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients, Europace, 15, 992, 10.1093/europace/eus419

Cleland, 2013, An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure, Eur Heart J, 34, 3547, 10.1093/eurheartj/eht290

Masoudi, 2014, Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study, Ann Intern Med, 160, 603, 10.7326/M13-1879

Woods, 2015, Individual patient data network meta-analysis of mortality effects of implantable cardiac devices, Heart, 101, 1800, 10.1136/heartjnl-2015-307634

Goldenberg, 2014, Survival with cardiac-resynchronization therapy in mild heart failure, N Engl J Med, 370, 1694, 10.1056/NEJMoa1401426

Sipahi, 2011, Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials, Arch Intern Med, 171, 1454, 10.1001/archinternmed.2011.247

Bryant, 2013, Association between QRS duration and outcome with cardiac resynchronization therapy: a systematic review and meta-analysis, J Electrocardiol, 46, 147, 10.1016/j.jelectrocard.2012.12.003

Birnie, 2013, Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT), Circ Heart Fail, 6, 1190, 10.1161/CIRCHEARTFAILURE.113.000380

Cunnington, 2015, Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials, Heart, 101, 1456, 10.1136/heartjnl-2014-306811

Healey, 2012, Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT), Circ Heart Fail, 5, 566, 10.1161/CIRCHEARTFAILURE.112.968867

Hayes, 2011, Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival, Heart Rhythm, 8, 1469, 10.1016/j.hrthm.2011.04.015

Yin, 2014, Effects of atrioventricular nodal ablation on permanent atrial fibrillation patients with cardiac resynchronization therapy: a systematic review and meta-analysis, Clin Cardiol, 37, 707, 10.1002/clc.22312

Tops, 2009, The effects of right ventricular apical pacing on ventricular function and dyssynchrony implications for therapy, J Am Coll Cardiol, 54, 764, 10.1016/j.jacc.2009.06.006

Dilaveris, 2006, Upgrade to biventricular pacing in patients with pacing-induced heart failure: can resynchronization do the trick?, Europace, 8, 352, 10.1093/europace/eul015

Gierula, 2013, Cardiac resynchronization therapy in pacemaker-dependent patients with left ventricular dysfunction, Europace, 15, 1609, 10.1093/europace/eut148

Curtis, 2013, Biventricular pacing for atrioventricular block and systolic dysfunction, N Engl J Med, 368, 1585, 10.1056/NEJMoa1210356

Ruschitzka, 2013, Cardiac-resynchronization therapy in heart failure with a narrow QRS complex, N Engl J Med, 369, 1395, 10.1056/NEJMoa1306687

Thibault, 2013, Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial, Circulation, 127, 873, 10.1161/CIRCULATIONAHA.112.001239

Muto, 2013, A randomized study of cardiac resynchronization therapy defibrillator versus dual-chamber implantable cardioverter-defibrillator in ischemic cardiomyopathy with narrow QRS: the NARROW-CRT study, Circ Arrhythm Electrophysiol, 6, 538, 10.1161/CIRCEP.113.000135

Wang, 2015, Effect of cardiac resynchronization therapy on patients with heart failure and narrow QRS complexes: a meta-analysis of five randomized controlled trials, J Interv Card Electrophysiol, 44, 71, 10.1007/s10840-015-0018-0

Shah, 2015, Cardiac-resynchronization therapy in patients with systolic heart failure and QRS interval ≤130 ms: insights from a meta-analysis, Europace, 17, 267, 10.1093/europace/euu214

Anand, 2015, Durable mechanical circulatory support versus organ transplantation: past, present, and future, Biomed Res Int, 2015, 849571, 10.1155/2015/849571

Boehmer, 2006, Cardiac failure: mechanical support strategies, Crit Care Med, 34, S268, 10.1097/01.CCM.0000232490.69771.28

Stevenson, 2009, INTERMACS profiles of advanced heart failure: the current picture, J Heart Lung Transplant, 28, 535, 10.1016/j.healun.2009.02.015

Taylor, 2014, Exercise-based rehabilitation for heart failure, Cochrane Database Syst Rev, CD003331

Taylor, 2012, Effects of exercise training for heart failure with preserved ejection fraction: a systematic review and meta-analysis of comparative studies, Int J Cardiol, 162, 6, 10.1016/j.ijcard.2012.05.070

Smart, 2004, Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity, Am J Med, 116, 693, 10.1016/j.amjmed.2003.11.033

O'Connor, 2009, Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial, JAMA, 301, 1439, 10.1001/jama.2009.454

McKelvie, 2008, Exercise training in patients with heart failure: clinical outcomes, safety, and indications, Heart Fail Rev, 13, 3, 10.1007/s10741-007-9052-z

Davies, 2010, Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis, Eur J Heart Fail, 12, 706, 10.1093/eurjhf/hfq056

Ades, 2013, Cardiac rehabilitation exercise and self-care for chronic heart failure, JACC Heart Fail, 1, 540, 10.1016/j.jchf.2013.09.002

Ismail, 2013, Clinical outcomes and cardiovascular responses to different exercise training intensities in patients with heart failure: a systematic review and meta-analysis, JACC Heart Fail, 1, 514, 10.1016/j.jchf.2013.08.006

Flynn, 2009, Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial, JAMA, 301, 1451, 10.1001/jama.2009.457

Warburton, 2016, Reflections on physical activity and health: what should we recommend?, Can J Cardiol, 32, 495, 10.1016/j.cjca.2016.01.024

Piepoli, 2011, Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation, Eur J Heart Fail, 13, 347, 10.1093/eurjhf/hfr017

Edelmann, 2011, Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study, J Am Coll Cardiol, 58, 1780, 10.1016/j.jacc.2011.06.054

Nolte, 2015, Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial, Eur J Prev Cardiol, 22, 582, 10.1177/2047487314526071

Kitzman, 2013, Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial, J Am Coll Cardiol, 62, 584, 10.1016/j.jacc.2013.04.033

Isaksen, 2012, Exercise training and cardiac rehabilitation in patients with implantable cardioverter defibrillators: a review of current literature focusing on safety, effects of exercise training, and the psychological impact of programme participation, Eur J Prev Cardiol, 19, 804, 10.1177/1741826711414624

Vanhees, 2004, Effect of exercise training in patients with an implantable cardioverter defibrillator, Eur Heart J, 25, 1120, 10.1016/j.ehj.2004.04.034

Doukky, 2016, Impact of Dietary Sodium Restriction On Heart Failure Outcomes, JACC Heart Fail, 4, 24, 10.1016/j.jchf.2015.08.007

Colin-Ramirez, 2015, The long-term effects of dietary sodium restriction on clinical outcomes in patients with heart failure. The SODIUM-HF (Study of Dietary Intervention Under 100 mmol in Heart Failure): a pilot study, Am Heart J, 169, 274, 10.1016/j.ahj.2014.11.013

McMahon, 2013, A randomized trial of dietary sodium restriction in CKD, J Am Soc Nephrol, 24, 2096, 10.1681/ASN.2013030285

Colin, 2010, Impact of a sodium and fluid restricted diet on clinical status in heart failure patients, Rev Chil Nutr, 37, 427

Arcand, 2011, A high-sodium diet is associated with acute decompensated heart failure in ambulatory heart failure patients: a prospective follow-up study, Am J Clin Nutr, 93, 332, 10.3945/ajcn.110.000174

Gupta, 2012, Dietary sodium intake in heart failure, Circulation, 126, 479, 10.1161/CIRCULATIONAHA.111.062430

Aliti, 2013, Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical trial, JAMA Intern Med, 173, 1058, 10.1001/jamainternmed.2013.552

Holst, 2008, Liberal versus restricted fluid prescription in stabilised patients with chronic heart failure: result of a randomised cross-over study of the effects on health-related quality of life, physical capacity, thirst and morbidity, Scand Cardiovasc J, 42, 316, 10.1080/14017430802071200

Travers, 2007, Fluid restriction in the management of decompensated heart failure: no impact on time to clinical stability, J Card Fail, 13, 128, 10.1016/j.cardfail.2006.10.012

Nicolas, 2002, The effect of controlled drinking in alcoholic cardiomyopathy, Ann Intern Med, 136, 192, 10.7326/0003-4819-136-3-200202050-00007

Macle, 2016, 2016 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation, Can J Cardiol, 32, 1170, 10.1016/j.cjca.2016.07.591

Chiang, 2012, Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry, Circ Arrhythm Electrophysiol, 5, 632, 10.1161/CIRCEP.112.970749

van Deursen, 2014, Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey, Eur J Heart Fail, 16, 103, 10.1002/ejhf.30

Maisel, 2003, Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy, Am J Cardiol, 91, 2D, 10.1016/S0002-9149(02)03373-8

Mamas, 2009, A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure, Eur J Heart Fail, 11, 676, 10.1093/eurjhf/hfp085

Wang, 2003, Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study, Circulation, 107, 2920, 10.1161/01.CIR.0000072767.89944.6E

Wolf, 1991, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke, 22, 983, 10.1161/01.STR.22.8.983

Roy, 2008, Rhythm control versus rate control for atrial fibrillation and heart failure, N Engl J Med, 358, 2667, 10.1056/NEJMoa0708789

Moe, 2014, The 2013 Canadian Cardiovascular Society heart failure management guidelines update: focus on rehabilitation and exercise and surgical coronary revascularization, Can J Cardiol, 30, 249, 10.1016/j.cjca.2013.10.010

Fox, 2001, Coronary artery disease as the cause of incident heart failure in the population, Eur Heart J, 22, 228, 10.1053/euhj.2000.2289

Loehr, 2008, Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study), Am J Cardiol, 101, 1016, 10.1016/j.amjcard.2007.11.061

Wright, 2011, J Am Coll Cardiol, 57, e215, 10.1016/j.jacc.2011.02.011

Shaw, 2008, Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy, Circulation, 117, 1283, 10.1161/CIRCULATIONAHA.107.743963

Grace, 2011, Systematizing inpatient referral to cardiac rehabilitation 2010: Canadian Association of Cardiac Rehabilitation and Canadian Cardiovascular Society joint position paper endorsed by the Cardiac Care Network of Ontario, Can J Cardiol, 27, 192, 10.1016/j.cjca.2010.12.007

Alderman, 1990, Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study, Circulation, 82, 1629, 10.1161/01.CIR.82.5.1629

1984, Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina, N Engl J Med, 311, 1333, 10.1056/NEJM198411223112102

Varnauskas, 1988, Twelve-year follow-up of survival in the randomized European Coronary Surgery Study, N Engl J Med, 319, 332, 10.1056/NEJM198808113190603

Yusuf, 1994, Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration, Lancet, 344, 563, 10.1016/S0140-6736(94)91963-1

Velazquez, 2007, The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial, J Thorac Cardiovasc Surg, 134, 1540, 10.1016/j.jtcvs.2007.05.069

Kunadian, 2011, Revascularization among patients with severe left ventricular dysfunction: a meta-analysis of observational studies, Eur J Heart Fail, 13, 773, 10.1093/eurjhf/hfr037

Hunt, 2009, J Am Coll Cardiol, 53, e1, 10.1016/j.jacc.2008.11.013

Gavazzi, 1997, Value of right ventricular ejection fraction in predicting short-term prognosis of patients with severe chronic heart failure, J Heart Lung Transplant, 16, 774

Meyer, 2010, Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure, Circulation, 121, 252, 10.1161/CIRCULATIONAHA.109.887570

Ghio, 2001, Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure, J Am Coll Cardiol, 37, 183, 10.1016/S0735-1097(00)01102-5

Gulati, 2013, The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy, Circulation, 128, 1623, 10.1161/CIRCULATIONAHA.113.002518

Pennell, 2004, Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report, J Cardiovasc Magn Reson, 6, 727, 10.1081/JCMR-200038581

Simonneau, 2013, Updated clinical classification of pulmonary hypertension, J Am Coll Cardiol, 62, D34, 10.1016/j.jacc.2013.10.029

Beck-da-Silva, 2004, Effect of bisoprolol on right ventricular function and brain natriuretic peptide in patients with heart failure, Congest Heart Fail, 10, 127, 10.1111/j.1527-5299.2004.03316.x

Quaife, 1998, Effects of carvedilol on right ventricular function in chronic heart failure, Am J Cardiol, 81, 247, 10.1016/S0002-9149(97)00874-6

Morrell, 2005, Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease, Respir Res, 6, 88, 10.1186/1465-9921-6-88

Dore, 2005, Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial, Circulation, 112, 2411, 10.1161/CIRCULATIONAHA.105.543470

McLaughlin, 2009, J Am Coll Cardiol, 53, 1573, 10.1016/j.jacc.2009.01.004

Warnes, 2008, Circulation, 118, 2395, 10.1161/CIRCULATIONAHA.108.190811

Galie, 2016, Eur Heart J, 37, 67, 10.1093/eurheartj/ehv317

Taichman, 2014, Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report, Chest, 146, 449, 10.1378/chest.14-0793

Jain, 2010, Prevalence of left ventricular regional dysfunction in arrhythmogenic right ventricular dysplasia: a tagged MRI study, Circ Cardiovasc Imaging, 3, 290, 10.1161/CIRCIMAGING.109.911313

Basso, 2009, Arrhythmogenic right ventricular cardiomyopathy, Lancet, 373, 1289, 10.1016/S0140-6736(09)60256-7

Sen-Chowdhry, 2010, Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment, Annu Rev Med, 61, 233, 10.1146/annurev.med.052208.130419

Bauce, 2008, Comparison of clinical features of arrhythmogenic right ventricular cardiomyopathy in men versus women, Am J Cardiol, 102, 1252, 10.1016/j.amjcard.2008.06.054

Marcus, 2010, Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria, Circulation, 121, 1533, 10.1161/CIRCULATIONAHA.108.840827

Borgquist, 2014, The diagnostic performance of imaging methods in ARVC using the 2010 Task Force criteria, Eur Heart J Cardiovasc Imaging, 15, 1219, 10.1093/ehjci/jeu109

Sarvari, 2011, Right ventricular mechanical dispersion is related to malignant arrhythmias: a study of patients with arrhythmogenic right ventricular cardiomyopathy and subclinical right ventricular dysfunction, Eur Heart J, 32, 1089, 10.1093/eurheartj/ehr069

te Riele, 2014, Arrhythmogenic right ventricular cardiomyopathy (ARVC): cardiovascular magnetic resonance update, J Cardiovasc Magn Reson, 16, 50, 10.1186/s12968-014-0050-8

Marcus, 2009, Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry, J Am Coll Cardiol, 54, 609, 10.1016/j.jacc.2009.04.052

Reiter, 1998, Importance of beta blockade in the therapy of serious ventricular arrhythmias, Am J Cardiol, 82, 9I, 10.1016/S0002-9149(98)00468-8

Corrado, 2010, Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia, Circulation, 122, 1144, 10.1161/CIRCULATIONAHA.109.913871

Zipes, 2006, J Am Coll Cardiol, 48, e247, 10.1016/j.jacc.2006.07.010

Leclercq, 1996, Determinants of spontaneous occurrence of sustained monomorphic ventricular tachycardia in right ventricular dysplasia, J Am Coll Cardiol, 28, 720, 10.1016/0735-1097(96)00233-1

Furlanello, 1998, Cardiac arrest and sudden death in competitive athletes with arrhythmogenic right ventricular dysplasia, Pacing Clin Electrophysiol, 21, 331, 10.1111/j.1540-8159.1998.tb01116.x

Burke, 1999, Sudden death in right ventricular dysplasia with minimal gross abnormalities, J Forensic Sci, 44, 438, 10.1520/JFS14482J

Chen, 2005, Clinical characteristics and treatment of constrictive pericarditis in Taiwan, Circ J, 69, 458, 10.1253/circj.69.458

Adler, 2015, Eur Heart J, 36, 2921, 10.1093/eurheartj/ehv318

Ling, 2000, Calcific constrictive pericarditis: is it still with us?, Ann Intern Med, 132, 444, 10.7326/0003-4819-132-6-200003210-00004

Welch, 2014, Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria, Circ Cardiovasc Imaging, 7, 526, 10.1161/CIRCIMAGING.113.001613

Oh, 1994, Diagnostic role of Doppler echocardiography in constrictive pericarditis, J Am Coll Cardiol, 23, 154, 10.1016/0735-1097(94)90514-2

Klein, 2013, American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography, J Am Soc Echocardiogr, 26, 965, 10.1016/j.echo.2013.06.023

Kusunose, 2013, Biventricular mechanics in constrictive pericarditis comparison with restrictive cardiomyopathy and impact of pericardiectomy, Circ Cardiovasc Imaging, 6, 399, 10.1161/CIRCIMAGING.112.000078

Nishimura, 2012, Hemodynamics in the cardiac catheterization laboratory of the 21st century, Circulation, 125, 2138, 10.1161/CIRCULATIONAHA.111.060319

Haley, 2004, Transient constrictive pericarditis: causes and natural history, J Am Coll Cardiol, 43, 271, 10.1016/j.jacc.2003.08.032

Yetkin, 2003, Recent surgical experience in chronic constrictive pericarditis, Tex Heart Inst J, 30, 27

Tirilomis, 1994, Pericardectomy for chronic constrictive pericarditis: risks and outcome, Eur J Cardiothorac Surg, 8, 487, 10.1016/1010-7940(94)90020-5

2011

Triposkiadis, 2016, Reframing the association and significance of co-morbidities in heart failure, Eur J Heart Fail, 18, 744, 10.1002/ejhf.600

Cleland, 2016, Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure, JAMA Cardiol, 1, 539, 10.1001/jamacardio.2016.1161

O'Meara, 2014, Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes, Circ Heart Fail, 7, 773, 10.1161/CIRCHEARTFAILURE.114.001100

O'Meara, 2006, Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program, Circulation, 113, 986, 10.1161/CIRCULATIONAHA.105.582577

Anand, 2005, Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT, Circulation, 112, 1121, 10.1161/CIRCULATIONAHA.104.512988

Horwich, 2002, Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure, J Am Coll Cardiol, 39, 1780, 10.1016/S0735-1097(02)01854-5

Ebner, 2016, The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure, Int J Cardiol, 205, 6, 10.1016/j.ijcard.2015.11.178

Felker, 2006, Anemia in patients with heart failure and preserved systolic function, Am Heart J, 151, 457, 10.1016/j.ahj.2005.03.056

Hillege, 2006, Renal function as a predictor of outcome in a broad spectrum of patients with heart failure, Circulation, 113, 671, 10.1161/CIRCULATIONAHA.105.580506

McClellan, 2002, Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study, J Am Soc Nephrol, 13, 1928, 10.1097/01.ASN.0000018409.45834.FA

Davis, 2017, All-payer analysis of heart failure hospitalization 30-day readmission: comorbidities matter, Am J Med, 130, 93.e9, 10.1016/j.amjmed.2016.07.030

Nordyke, 2004, Impact of anemia on hospitalization time, charges, and mortality in patients with heart failure, Value Health, 7, 464, 10.1111/j.1524-4733.2004.74009.x

Lund, 2014, Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction, Eur J Heart Fail, 16, 992, 10.1002/ejhf.137

Ather, 2012, Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction, J Am Coll Cardiol, 59, 998, 10.1016/j.jacc.2011.11.040

Klip, 2013, Iron deficiency in chronic heart failure: an international pooled analysis, Am Heart J, 165, 575, 10.1016/j.ahj.2013.01.017

Jankowska, 2010, Iron deficiency: an ominous sign in patients with systolic chronic heart failure, Eur Heart J, 31, 1872, 10.1093/eurheartj/ehq158

Silverberg, 2015, Is correction of iron deficiency a new addition to the treatment of the heart failure?, Int J Mol Sci, 16, 14056, 10.3390/ijms160614056

Cohen-Solal, 2014, Iron deficiency: an emerging therapeutic target in heart failure, Heart, 100, 1414, 10.1136/heartjnl-2014-305669

O'Meara, 2010, Management of anemia and iron deficiency in heart failure, Curr Treat Options Cardiovasc Med, 12, 532, 10.1007/s11936-010-0095-4

Dalimunthe, 2016, Usefulness of reticulocyte hemoglobin equivalent in management of regular hemodialysis patients with iron deficiency anemia, Rom J Intern Med, 54, 31

Jankowska, 2013, Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives, Eur Heart J, 34, 816, 10.1093/eurheartj/ehs224

Avni, 2012, Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis, Eur J Heart Fail, 14, 423, 10.1093/eurjhf/hfs017

Qian, 2016, The efficacy and safety of iron supplementation in patients with heart failure and iron deficiency: a systematic review and meta-analysis, Can J Cardiol, 32, 151, 10.1016/j.cjca.2015.06.009

Ponikowski, 2015, Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger, Eur Heart J, 36, 657, 10.1093/eurheartj/ehu385

Anker, 2009, Ferric carboxymaltose in patients with heart failure and iron deficiency, N Engl J Med, 361, 2436, 10.1056/NEJMoa0908355

van Veldhuisen, 2017, Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency, Circulation, 136, 1374, 10.1161/CIRCULATIONAHA.117.027497

O'Meara, 2016, Heart failure, iron deficiency, and supplementation: where do we stand?, Can J Cardiol, 32, 148, 10.1016/j.cjca.2015.07.725

Moe, 2015, The 2014 Canadian Cardiovascular Society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications, Can J Cardiol, 31, 3, 10.1016/j.cjca.2014.10.022

Lewis, 2016, Oral iron therapy for heart failure with reduced ejection fraction: design and rationale for oral iron repletion effects on oxygen uptake in heart failure, Circ Heart Fail, 9, e000345, 10.1161/CIRCHEARTFAILURE.115.000345

Ghali, 2008, Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia, Circulation, 117, 526, 10.1161/CIRCULATIONAHA.107.698514

Swedberg, 2013, Treatment of anemia with darbepoetin alfa in systolic heart failure, N Engl J Med, 368, 1210, 10.1056/NEJMoa1214865

Arora, 2014, Anemia and iron deficiency in heart failure, Heart Fail Clin, 10, 281, 10.1016/j.hfc.2013.11.002

Collister, 2016, The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis, Ann Intern Med, 164, 472, 10.7326/M15-1839

Margulies, 2016, Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial, JAMA, 316, 500, 10.1001/jama.2016.10260

Jorsal, 2017, Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial, Eur J Heart Fail, 19, 69, 10.1002/ejhf.657

Smith, 2006, Renal impairment and outcomes in heart failure: systematic review and meta-analysis, J Am Coll Cardiol, 47, 1987, 10.1016/j.jacc.2005.11.084

Harnett, 1995, Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors, Kidney Int, 47, 884, 10.1038/ki.1995.132

Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16, 31, 10.1159/000180580

2002, K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, Am J Kidney Dis, 39, S1

Bock, 2010, Cardiorenal syndrome: new perspectives, Circulation, 121, 2592, 10.1161/CIRCULATIONAHA.109.886473

Ronco, 2010, Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative, Eur Heart J, 31, 703, 10.1093/eurheartj/ehp507

Mullens, 2009, Importance of venous congestion for worsening of renal function in advanced decompensated heart failure, J Am Coll Cardiol, 53, 589, 10.1016/j.jacc.2008.05.068

Damman, 2009, Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease, J Am Coll Cardiol, 53, 582, 10.1016/j.jacc.2008.08.080

Braam, 2014, Cardiorenal syndrome–current understanding and future perspectives, Nat Rev Nephrol, 10, 48, 10.1038/nrneph.2013.250

Palevsky, 2005, Renal replacement therapy I: indications and timing, Crit Care Clin, 21, 347, 10.1016/j.ccc.2004.12.002

Cice, 2003, Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial, J Am Coll Cardiol, 41, 1438, 10.1016/S0735-1097(03)00241-9

Winkelmayer, 2006, Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction, Am J Kidney Dis, 47, 301, 10.1053/j.ajkd.2005.10.009

Zannad, 2006, Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies, Kidney Int, 70, 1318, 10.1038/sj.ki.5001657

Suzuki, 2008, Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial, Am J Kidney Dis, 52, 501, 10.1053/j.ajkd.2008.04.031

Cice, 2010, Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial, J Am Coll Cardiol, 56, 1701, 10.1016/j.jacc.2010.03.105

Hussain, 2003, Is spironolactone safe for dialysis patients?, Nephrol Dial Transplant, 18, 2364, 10.1093/ndt/gfg413

Saudan, 2003, Safety of low-dose spironolactone administration in chronic haemodialysis patients, Nephrol Dial Transplant, 18, 2359, 10.1093/ndt/gfg388

Gross, 2005, Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients, Am J Kidney Dis, 46, 94, 10.1053/j.ajkd.2005.03.005

Taheri, 2009, Spironolactone in chronic hemodialysis patients improves cardiac function, Saudi J Kidney Dis Transpl, 20, 392

Knoll, 2005, Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation, CMAJ, 173, S1, 10.1503/cmaj.1041588

Ferreira, 2002, Cardiovascular effects of successful renal transplantation: a 1-year sequential study of left ventricular morphology and function, and 24-hour blood pressure profile, Transplantation, 74, 1580, 10.1097/00007890-200212150-00016

Wali, 2005, Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease, J Am Coll Cardiol, 45, 1051, 10.1016/j.jacc.2004.11.061

Parfrey, 1995, Impact of renal transplantation on uremic cardiomyopathy, Transplantation, 60, 908, 10.1097/00007890-199511150-00005

Fonarow, 2004, Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry, Heart Fail Rev, 9, 179, 10.1007/s10741-005-6127-6

Eshaghian, 2006, Relation of loop diuretic dose to mortality in advanced heart failure, Am J Cardiol, 97, 1759, 10.1016/j.amjcard.2005.12.072

Butler, 2004, Relationship between heart failure treatment and development of worsening renal function among hospitalized patients, Am Heart J, 147, 331, 10.1016/j.ahj.2003.08.012

Bart, 2009, Treatment of congestion in congestive heart failure: ultrafiltration is the only rational initial treatment of volume overload in decompensated heart failure, Circ Heart Fail, 2, 499, 10.1161/CIRCHEARTFAILURE.109.863381

Bart, 2005, Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial, J Am Coll Cardiol, 46, 2043, 10.1016/j.jacc.2005.05.098

Costanzo, 2007, Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure, J Am Coll Cardiol, 49, 675, 10.1016/j.jacc.2006.07.073

Bart, 2012, Ultrafiltration in decompensated heart failure with cardiorenal syndrome, N Engl J Med, 367, 2296, 10.1056/NEJMoa1210357

Lyons, 2015, Heart failure and sleep apnea, Can J Cardiol, 31, 898, 10.1016/j.cjca.2015.04.017

Cormican, 2005, Sleep disordered breathing and its treatment in congestive heart failure, Heart, 91, 1265, 10.1136/hrt.2004.048314

Ferrier, 2005, Sleep-disordered breathing occurs frequently in stable outpatients with congestive heart failure, Chest, 128, 2116, 10.1378/chest.128.4.2116

1999, Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force, Sleep, 22, 667, 10.1093/sleep/22.5.667

Sin, 2000, Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration, Circulation, 102, 61, 10.1161/01.CIR.102.1.61

Bradley, 2005, Continuous positive airway pressure for central sleep apnea and heart failure, N Engl J Med, 353, 2025, 10.1056/NEJMoa051001

Teschler, 2001, Adaptive pressure support servo-ventilation: a novel treatment for Cheyne-Stokes respiration in heart failure, Am J Respir Crit Care Med, 164, 614, 10.1164/ajrccm.164.4.9908114

Cowie, 2015, Adaptive servo-ventilation for central sleep apnea in systolic heart failure, N Engl J Med, 373, 1095, 10.1056/NEJMoa1506459

McCormack, 2007, Adding “value” to clinical practice guidelines, Can Fam Physician, 53, 1326

Adams, 2005, Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE), Am Heart J, 149, 209, 10.1016/j.ahj.2004.08.005

Arnold, 2007, Canadian Cardiovascular Society consensus conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers, Can J Cardiol, 23, 21, 10.1016/S0828-282X(07)70211-8

Nohria, 2003, Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure, J Am Coll Cardiol, 41, 1797, 10.1016/S0735-1097(03)00309-7

Ghali, 1988, Precipitating factors leading to decompensation of heart failure. Traits among urban blacks, Arch Intern Med, 148, 2013, 10.1001/archinte.1988.00380090087021

Nieminen, 2006, EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population, Eur Heart J, 27, 2725, 10.1093/eurheartj/ehl193

Van de Werf, 2003, Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology, Eur Heart J, 24, 28, 10.1016/S0195-668X(02)00618-8

Maisel, 2002, Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure, N Engl J Med, 347, 161, 10.1056/NEJMoa020233

Moe, 2007, N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study, Circulation, 115, 3103, 10.1161/CIRCULATIONAHA.106.666255

Baggish, 2006, A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the emergency department (PRIDE) Acute Heart Failure Score, Am Heart J, 151, 48, 10.1016/j.ahj.2005.02.031

Steinhart, 2009, Improving the diagnosis of acute heart failure using a validated prediction model, J Am Coll Cardiol, 54, 1515, 10.1016/j.jacc.2009.05.065

Park, 2010, Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction, Heart, 96, 533, 10.1136/hrt.2009.175257

Sepehrvand, 2016, Oxygen therapy in patients with acute heart failure: friend or foe?, JACC Heart Fail, 4, 783, 10.1016/j.jchf.2016.03.026

Gray, 2010, Diuretic, opiate and nitrate use in severe acidotic acute cardiogenic pulmonary oedema: analysis from the 3CPO trial, QJM, 103, 573, 10.1093/qjmed/hcq077

Peacock, 2008, Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis, Emerg Med J, 25, 205, 10.1136/emj.2007.050419

Iakobishvili, 2011, Use of intravenous morphine for acute decompensated heart failure in patients with and without acute coronary syndromes, Acute Card Care, 13, 76, 10.3109/17482941.2011.575165

Gray, 2008, Noninvasive ventilation in acute cardiogenic pulmonary edema, N Engl J Med, 359, 142, 10.1056/NEJMoa0707992

Vital, 2013, Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema, Cochrane Database Syst Rev, 5, CD005351

Felker, 2011, Diuretic strategies in patients with acute decompensated heart failure, N Engl J Med, 364, 797, 10.1056/NEJMoa1005419

Brater, 1998, Diuretic therapy, N Engl J Med, 339, 387, 10.1056/NEJM199808063390607

Wilson, 1981, Effect of diuresis on the performance of the failing left ventricle in man, Am J Med, 70, 234, 10.1016/0002-9343(81)90755-5

Gardtman, 2000, Has an intensified treatment in the ambulance of patients with acute severe left heart failure improved the outcome?, Eur J Emerg Med, 7, 15, 10.1097/00063110-200003000-00004

Ducharme, 2005, Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial, CMAJ, 173, 40, 10.1503/cmaj.1041137

Kiyingi, 1990, Metolazone in treatment of severe refractory congestive cardiac failure, Lancet, 335, 29, 10.1016/0140-6736(90)90148-X

van Vliet, 1993, Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor, Am J Cardiol, 71, 21A, 10.1016/0002-9149(93)90241-4

Wu, 2014, Loop diuretic strategies in patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials, J Crit Care, 29, 2, 10.1016/j.jcrc.2013.10.009

ter Maaten, 2015, Diuretic response in acute heart failure-an analysis from ASCEND-HF, Am Heart J, 170, 313, 10.1016/j.ahj.2015.05.003

Valente, 2014, Diuretic response in acute heart failure: clinical characteristics and prognostic significance, Eur Heart J, 35, 1284, 10.1093/eurheartj/ehu065

Alexander, 2015, Lack of evidence for intravenous vasodilators in ED patients with acute heart failure: a systematic review, Am J Emerg Med, 33, 133, 10.1016/j.ajem.2014.09.009

Cotter, 1998, Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema, Lancet, 351, 389, 10.1016/S0140-6736(97)08417-1

2002, Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial, JAMA, 287, 1531

O'Connor, 2011, Effect of nesiritide in patients with acute decompensated heart failure, N Engl J Med, 365, 32, 10.1056/NEJMoa1100171

Mullens, 2008, Sodium nitroprusside for advanced low-output heart failure, J Am Coll Cardiol, 52, 200, 10.1016/j.jacc.2008.02.083

Packer, 2017, Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure, Eur J Heart Fail, 19, 673, 10.1002/ejhf.698

Felker, 2015, Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure), JACC Heart Fail, 3, 193, 10.1016/j.jchf.2014.09.008

Cleland, 2006, Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE, Eur J Heart Fail, 8, 105, 10.1016/j.ejheart.2005.12.003

Cuffe, 2002, Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial, JAMA, 287, 1541, 10.1001/jama.287.12.1541

Felker, 2003, Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study, J Am Coll Cardiol, 41, 997, 10.1016/S0735-1097(02)02968-6

Packer, 2013, Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure, JACC Heart Fail, 1, 103, 10.1016/j.jchf.2012.12.004

Teerlink, 2016, Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: the ATOMIC-AHF study, J Am Coll Cardiol, 67, 1444, 10.1016/j.jacc.2016.01.031

Chen, 2013, Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial, JAMA, 310, 2533, 10.1001/jama.2013.282190

Triposkiadis, 2014, Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial, Int J Cardiol, 172, 115, 10.1016/j.ijcard.2013.12.276

Ezekowitz, 2008, Acute heart failure in the emergency department: short and long-term outcomes of elderly patients with heart failure, Eur J Heart Fail, 10, 308, 10.1016/j.ejheart.2008.01.014

Jondeau, 2009, B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode, Eur Heart J, 30, 2186, 10.1093/eurheartj/ehp323

Gheorghiade, 2004, Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial, JAMA, 291, 1963, 10.1001/jama.291.16.1963

Schrier, 2006, Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia, N Engl J Med, 355, 2099, 10.1056/NEJMoa065181

Konstam, 2007, Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial, JAMA, 297, 1319, 10.1001/jama.297.12.1319

Hauptman, 2013, Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan, J Card Fail, 19, 390, 10.1016/j.cardfail.2013.04.001

Salah, 2015, Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality, independent of N-terminal pro-B-type natriuretic peptide levels: an individual patient data analysis, Am Heart J, 170, 531, 10.1016/j.ahj.2015.06.003

Lee, 2014, Risk stratification in acute heart failure, Can J Cardiol, 30, 312, 10.1016/j.cjca.2014.01.001

Collins, 2015, Identification of emergency department patients with acute heart failure at low risk for 30-day adverse events: the STRATIFY decision tool, JACC Heart Fail, 3, 737, 10.1016/j.jchf.2015.05.007

van Diepen, 2015, Variation in critical care unit admission rates and outcomes for patients with acute coronary syndromes or heart failure among high- and low-volume cardiac hospitals, J Am Heart Assoc, 4, e001708, 10.1161/JAHA.114.001708

Cecconi, 2007, Haemodynamic monitoring in acute heart failure, Heart Fail Rev, 12, 105, 10.1007/s10741-007-9010-9

Binanay, 2005, Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial, JAMA, 294, 1625, 10.1001/jama.294.13.1625

Shah, 2005, Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials, JAMA, 294, 1664, 10.1001/jama.294.13.1664

Pandey, 2016, Use of pulmonary artery catheterization in US patients with heart failure, 2001-2012, JAMA Intern Med, 176, 129, 10.1001/jamainternmed.2015.6190

Marik, 1999, Pulmonary artery catheterization and esophageal Doppler monitoring in the ICU, Chest, 116, 1085, 10.1378/chest.116.4.1085

Maron, 2014, Hypertrophic cardiomyopathy present and future, with translation into contemporary cardiovascular medicine, J Am Coll Cardiol, 64, 83, 10.1016/j.jacc.2014.05.003

Spirito, 1989, Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population, N Engl J Med, 320, 749, 10.1056/NEJM198903233201201

Biagini, 2005, Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients, J Am Coll Cardiol, 46, 1543, 10.1016/j.jacc.2005.04.062

Spirito, 1987, Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy, Am J Cardiol, 60, 123, 10.1016/0002-9149(87)90998-2

Child, 1986, Cardiac involvement in Friedreich's ataxia: a clinical study of 75 patients, J Am Coll Cardiol, 7, 1370, 10.1016/S0735-1097(86)80159-0

Sarkozy, 2003, Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes, J Med Genet, 40, 704, 10.1136/jmg.40.9.704

Maron, 1999, Clinical course of hypertrophic cardiomyopathy in a regional United States cohort, JAMA, 281, 650, 10.1001/jama.281.7.650

Karamitsos, 2009, The role of cardiovascular magnetic resonance imaging in heart failure, J Am Coll Cardiol, 54, 1407, 10.1016/j.jacc.2009.04.094

Nagueh, 2001, Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy, Circulation, 104, 128, 10.1161/01.CIR.104.2.128

Nishimura, 2004, Clinical practice. Hypertrophic obstructive cardiomyopathy, N Engl J Med, 350, 1320, 10.1056/NEJMcp030779

Artz, 2000, Restrictive cardiomyopathy, Curr Treat Options Cardiovasc Med, 2, 431, 10.1007/s11936-000-0038-6

Seward, 2010, Infiltrative cardiovascular diseases: cardiomyopathies that look alike, J Am Coll Cardiol, 55, 1769, 10.1016/j.jacc.2009.12.040

Kushwaha, 1997, Restrictive cardiomyopathy, N Engl J Med, 336, 267, 10.1056/NEJM199701233360407

Mogensen, 2003, Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations, J Clin Invest, 111, 209, 10.1172/JCI200316336

Ammash, 2000, Clinical profile and outcome of idiopathic restrictive cardiomyopathy, Circulation, 101, 2490, 10.1161/01.CIR.101.21.2490

Gertz, 1999, Amyloidosis, Hematol Oncol Clin North Am, 13, 1211, 10.1016/S0889-8588(05)70122-2

Reisinger, 1997, Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement, J Am Coll Cardiol, 30, 1046, 10.1016/S0735-1097(97)00267-2

Rocken, 2002, Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation, Circulation, 106, 2091, 10.1161/01.CIR.0000034511.06350.DF

Clarke, 2007, Narrative review: Fabry disease, Ann Intern Med, 146, 425, 10.7326/0003-4819-146-6-200703200-00007

Dubrey, 1997, Signal-averaged electrocardiography in patients with AL (primary) amyloidosis, Am Heart J, 134, 994, 10.1016/S0002-8703(97)70017-6

Desai, 2010, Cardiac amyloidosis: approaches to diagnosis and management, Cardiol Rev, 18, 1, 10.1097/CRD.0b013e3181bdba8f

Falk, 2016, AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy, J Am Coll Cardiol, 68, 1323, 10.1016/j.jacc.2016.06.053

Lachmann, 2002, Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis, N Engl J Med, 346, 1786, 10.1056/NEJMoa013354

Cacoub, 2000, Amyloidosis and cardiac involvement, Ann Med Interne (Paris), 151, 611

Selvanayagam, 2007, Evaluation and management of the cardiac amyloidosis, J Am Coll Cardiol, 50, 2101, 10.1016/j.jacc.2007.08.028

Appleton, 1988, Demonstration of restrictive ventricular physiology by Doppler echocardiography, J Am Coll Cardiol, 11, 757, 10.1016/0735-1097(88)90208-2

Choi, 2007, J Am Soc Echocardiogr, 20, 738, 10.1016/j.echo.2006.11.005

Bellenger, 2000, Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance, J Cardiovasc Magn Reson, 2, 271, 10.3109/10976640009148691

Kim, 1999, Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function, Circulation, 100, 1992, 10.1161/01.CIR.100.19.1992

Friedrich, 1998, Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis, Circulation, 97, 1802, 10.1161/01.CIR.97.18.1802

Maceira, 2005, Cardiovascular magnetic resonance in cardiac amyloidosis, Circulation, 111, 186, 10.1161/01.CIR.0000152819.97857.9D

Uemura, 1999, Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies, Am Heart J, 138, 299, 10.1016/S0002-8703(99)70115-8

Schulz-Menger, 2006, Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovascular magnetic resonance, Heart, 92, 399, 10.1136/hrt.2004.058016

Singh, 2005, Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: a preliminary report, Lupus, 14, 137, 10.1191/0961203305lu2050oa

Petersen, 2005, Subendocardial and papillary muscle involvement in a patient with Churg-Strauss syndrome, detected by contrast enhanced cardiovascular magnetic resonance, Heart, 91, e9, 10.1136/hrt.2004.050070

Westwood, 2003, Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia, J Magn Reson Imaging, 18, 616, 10.1002/jmri.10396

Tanaka, 1997, Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy, J Am Coll Cardiol, 29, 168, 10.1016/S0735-1097(96)00438-X

Canada S. Census of Population. 2006. Available at: http://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SurvId=30216&InstaId=30219&SDDS=3901. Accessed March 2, 2016.

Balsa, 2003, Prejudice, clinical uncertainty and stereotyping as sources of health disparities, J Health Econ, 22, 89, 10.1016/S0167-6296(02)00098-X

Gerend, 2008, Social determinants of black-white disparities in breast cancer mortality: a review, Cancer Epidemiol Biomarkers Prev, 17, 2913, 10.1158/1055-9965.EPI-07-0633

Groman, 2004, Racial and ethnic disparities in health care: a position paper of the American College of Physicians, Ann Intern Med, 141, 226, 10.7326/0003-4819-141-3-200408030-00015

Woolf, 2008, The health impact of resolving racial disparities: an analysis of US mortality data, Am J Public Health, 98, S26, 10.2105/AJPH.98.Supplement_1.S26

Colvin, 2015, Heart failure in non-Caucasians, women, and older adults: a white paper on special populations from the Heart Failure Society of America Guideline Committee, J Card Fail, 21, 674, 10.1016/j.cardfail.2015.05.013

Sanderson, 1999, Beta-blockade in heart failure: a comparison of carvedilol with metoprolol, J Am Coll Cardiol, 34, 1522, 10.1016/S0735-1097(99)00367-8

Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet, 364, 937, 10.1016/S0140-6736(04)17018-9

Tu, 2015, The incidence of major cardiovascular events in immigrants to Ontario, Canada: the CANHEART Immigrant Study, Circulation, 132, 1549, 10.1161/CIRCULATIONAHA.115.015345

Mentz, 2016, Heart failure clinical trials in East and Southeast Asia: understanding the importance and defining the next steps, JACC Heart Fail, 4, 419, 10.1016/j.jchf.2016.01.013

Krauser, 2006, Neither race nor gender influences the usefulness of amino-terminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the emergency department (PRIDE) substudy, J Card Fail, 12, 452, 10.1016/j.cardfail.2006.04.005

Ajayi, 1989, Enalapril in African patients with congestive cardiac failure, Br J Clin Pharmacol, 27, 400, 10.1111/j.1365-2125.1989.tb05385.x

Thorne, 2006, Risks of contraception and pregnancy in heart disease, Heart, 92, 1520, 10.1136/hrt.2006.095240

Pijuan-Domènech, 2015, Cardiac complications during pregnancy are better predicted with the modified WHO risk score, Int J Cardiol, 195, 149, 10.1016/j.ijcard.2015.05.076

Regitz-Zagrosek, 2011, Cardiovascular diseases in pregnancy, Dtsch Arztebl Int, 108, 267

Alonso-Gonzalez, 2014, Treating cardiac disease in pregnancy, Womens Health (Lond), 10, 79, 10.2217/WHE.13.70

Herrey, 2014, Pregnancy in inherited and acquired cardiomyopathies, Best Pract Res Clin Obstet Gynaecol, 28, 563, 10.1016/j.bpobgyn.2014.03.010

Howlett, 2010, The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs, Can J Cardiol, 26, 185, 10.1016/S0828-282X(10)70367-6

European Society of Gynecology (ESG), 2011, ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC), Eur Heart J, 32, 3147, 10.1093/eurheartj/ehr218

Cooper, 2006, Major congenital malformations after first-trimester exposure to ACE inhibitors, N Engl J Med, 354, 2443, 10.1056/NEJMoa055202

Schaefer, 2003, Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity, Birth Defects Res A Clin Mol Teratol, 67, 591, 10.1002/bdra.10081

Lydakis, 1999, Atenolol and fetal growth in pregnancies complicated by hypertension, Am J Hypertens, 12, 541, 10.1016/S0895-7061(99)00031-X

Pearl, 1995, Familial occurrence of peripartum cardiomyopathy, Am Heart J, 129, 421, 10.1016/0002-8703(95)90032-2

Fett, 2007, Viral infection as a possible trigger for the development of peripartum cardiomyopathy, Int J Gynaecol Obstet, 97, 149, 10.1016/j.ijgo.2007.01.012

Sliwa, 2006, Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients, Eur Heart J, 27, 441, 10.1093/eurheartj/ehi481

Hilfiker-Kleiner, 2007, A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy, Cell, 128, 589, 10.1016/j.cell.2006.12.036

Sliwa, 2010, Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy, Eur J Heart Fail, 12, 767, 10.1093/eurjhf/hfq120

Li, 2016, Clinical characteristics and long-term predictors of persistent left ventricular systolic dysfunction in peripartum cardiomyopathy, Can J Cardiol, 32, 362, 10.1016/j.cjca.2015.07.733

Forster, 2008, Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy, Eur J Heart Fail, 10, 861, 10.1016/j.ejheart.2008.07.005

Desplantie, 2015, The medical treatment of new-onset peripartum cardiomyopathy: a systematic review of prospective studies, Can J Cardiol, 31, 1421, 10.1016/j.cjca.2015.04.029

Sliwa, 2010, Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study, Circulation, 121, 1465, 10.1161/CIRCULATIONAHA.109.901496

Haghikia, 2015, Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy, Clin Res Cardiol, 104, 911, 10.1007/s00392-015-0869-5

Ballo, 2012, Peripartum cardiomyopathy presenting with predominant left ventricular diastolic dysfunction: efficacy of bromocriptine, Case Rep Med, 2012, 476903, 10.1155/2012/476903

Elkayam, 2011, Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management, J Am Coll Cardiol, 58, 659, 10.1016/j.jacc.2011.03.047

McNamara, 2015, Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study (Investigations of Pregnancy-Associated Cardiomyopathy), J Am Coll Cardiol, 66, 905, 10.1016/j.jacc.2015.06.1309

Goland, 2009, Clinical profile and predictors of complications in peripartum cardiomyopathy, J Card Fail, 15, 645, 10.1016/j.cardfail.2009.03.008

Elkayam, 2001, Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy, N Engl J Med, 344, 1567, 10.1056/NEJM200105243442101

Fett, 2010, Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers, Int J Gynaecol Obstet, 109, 34, 10.1016/j.ijgo.2009.10.011

Elkayam, 2014, Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy, J Am Coll Cardiol, 64, 1629, 10.1016/j.jacc.2014.07.961

Aretz, 1987, Myocarditis: the Dallas criteria, Hum Pathol, 18, 619, 10.1016/S0046-8177(87)80363-5

Baughman, 2006, Diagnosis of myocarditis: death of Dallas criteria, Circulation, 113, 593, 10.1161/CIRCULATIONAHA.105.589663

Mason, 1995, A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators, N Engl J Med, 333, 269, 10.1056/NEJM199508033330501

Felker, 1999, The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients, Medicine (Baltimore), 78, 270, 10.1097/00005792-199907000-00005

Dec, 1985, Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome, N Engl J Med, 312, 885, 10.1056/NEJM198504043121404

D'Ambrosio, 2001, The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review, Heart, 85, 499, 10.1136/heart.85.5.499

Smith, 1997, Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates, Circulation, 95, 163, 10.1161/01.CIR.95.1.163

Pinamonti, 1988, Echocardiographic findings in myocarditis, Am J Cardiol, 62, 285, 10.1016/0002-9149(88)90226-3

Radunski, 2014, CMR in patients with severe myocarditis: diagnostic value of quantitative tissue markers including extracellular volume imaging, JACC Cardiovasc Imaging, 7, 667, 10.1016/j.jcmg.2014.02.005

Zagrosek, 2009, Cardiac magnetic resonance monitors reversible and irreversible myocardial injury in myocarditis, JACC Cardiovasc Imaging, 2, 131, 10.1016/j.jcmg.2008.09.014

Bohnen, 2015, Performance of t1 and t2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure, Circ Cardiovasc Imaging, 8, e003073, 10.1161/CIRCIMAGING.114.003073

Bonner, 2016, Myocardial T2 mapping increases noninvasive diagnostic accuracy for biopsy-proven myocarditis, JACC Cardiovasc Imaging, 9, 1467, 10.1016/j.jcmg.2015.11.014

Leone, 2012, 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology, Cardiovasc Pathol, 21, 245, 10.1016/j.carpath.2011.10.001

Caforio, 2007, A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis, Eur Heart J, 28, 1326, 10.1093/eurheartj/ehm076

Caforio, 2013, Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, 34, 2636, 10.1093/eurheartj/eht210

Frustaci, 2009, Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study, Eur Heart J, 30, 1995, 10.1093/eurheartj/ehp249

Robinson, 2015, Intravenous immunoglobulin for presumed viral myocarditis in children and adults, Cochrane Database Syst Rev, CD004370

Kishimoto, 2014, Therapy with immunoglobulin in patients with acute myocarditis and cardiomyopathy: analysis of leukocyte balance, Heart Vessels, 29, 336, 10.1007/s00380-013-0368-4

Goland, 2008, Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: series of six patients and review of literature, Can J Cardiol, 24, 571, 10.1016/S0828-282X(08)70638-X

Wagner, 2006, Bridge to recovery by mechanical ventricular assist (VAD) – a successful therapy for cardiac failure due to acute myocarditis (AM), J Heart Lung Transplant, 25, S123, 10.1016/j.healun.2005.11.238

Acker, 2001, Mechanical circulatory support for patients with acute-fulminant myocarditis, Ann Thorac Surg, 71, S73, 10.1016/S0003-4975(00)02628-X

Wagner, 2003, Long-term follow-up of patients paragraph sign with acute myocarditis by magnetic paragraph sign resonance imaging, MAGMA, 16, 17, 10.1007/s10334-003-0007-7

Wagner, 1996, Organizing care for patients with chronic illness, Milbank Q, 74, 511, 10.2307/3350391

Herr, 2014, Heart failure symptom relationships: a systematic review, J Cardiovasc Nurs, 29, 416, 10.1097/JCN.0b013e31829b675e

2010

Zavertnik, 2014, Self-care in older adults with heart failure: an integrative review, Clin Nurse Spec, 28, 19, 10.1097/NUR.0000000000000021

Currie, 2015, The association between mild cognitive impairment and self-care in adults with chronic heart failure: a systematic review and narrative synthesis, J Cardiovasc Nurs, 30, 382, 10.1097/JCN.0000000000000173

Heckman, 2014, The journey of the frail older adult with heart failure: implications for management and health care systems, Rev Clin Gerontol, 24, 269, 10.1017/S0959259814000136

Leto, 2014, Cognitive impairment in heart failure patients, J Geriatr Cardiol, 11, 316

Sokoreli, 2016, Depression and anxiety as predictors of mortality among heart failure patients: systematic review and meta-analysis, Heart Fail Rev, 21, 49, 10.1007/s10741-015-9517-4

Stewart, 2016, Establishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): a multidisciplinary position statement, Int J Cardiol, 212, 1, 10.1016/j.ijcard.2016.03.001

Jha, 2015, Frailty in advanced heart failure: a systematic review, Heart Fail Rev, 20, 553, 10.1007/s10741-015-9493-8

Svanstrom, 2015, Use of different types of angiotensin converting enzyme inhibitors and mortality in systolic heart failure, Int J Cardiol, 182, 90, 10.1016/j.ijcard.2014.12.092

Vorilhon, 2015, Heart failure prognosis and management in over-80-year-old patients: data from a French national observational retrospective cohort, Eur J Clin Pharmacol, 71, 251, 10.1007/s00228-014-1794-7

Forman, 2013, Heart failure in very old adults, Curr Heart Fail Rep, 10, 387, 10.1007/s11897-013-0163-7

Mujib, 2013, Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction, Am J Med, 126, 401, 10.1016/j.amjmed.2013.01.004

Scherer, 2013, Determinants of change in quality of life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD), Eur J Intern Med, 24, 333, 10.1016/j.ejim.2013.01.003

Man, 2012, Systolic heart failure in the elderly: optimizing medical management, Heart Fail Rev, 17, 563, 10.1007/s10741-011-9282-y

Savioli Neto, 2009, ACE inhibitors and plasma B-type natriuretic peptide levels in elderly patients with heart failure, Arq Bras Cardiol, 92, 320

Dekleva, 2012, Beta blockers therapy is associated with improved left ventricular systolic function and sustained exercise capacity in elderly patients with heart failure. CIBIS-ELD sub-study, Aging Clin Exp Res, 24, 675, 10.1007/BF03654848

Tannenbaum, 2014, Managing therapeutic competition in patients with heart failure, lower urinary tract symptoms and incontinence, Drugs Aging, 31, 93, 10.1007/s40266-013-0145-1

Chisholm, 2017, Orthostatic hypotension - pathophysiology, assessment, treatment, and the paradox of supine hypertension - a review, Intern Med J, 47, 370, 10.1111/imj.13171

Gorelik, 2016, Heart failure and orthostatic hypotension, Heart Fail Rev, 21, 529, 10.1007/s10741-016-9541-z

Muscedere, 2016, Screening for frailty in Canada's health care system: a time for action, Can J Aging, 35, 1, 10.1017/S0714980816000301

Heckman, 2016, Integrating frailty assessment into cardiovascular decision-making, Can J Cardiol, 32, 139, 10.1016/j.cjca.2015.06.011

Rolfson, 2006, Validity and reliability of the Edmonton Frail Scale, Age Ageing, 35, 526, 10.1093/ageing/afl041

Rockwood, 2007, A comparison of two approaches to measuring frailty in elderly people, J Gerontol A Biol Sci Med Sci, 62, 738, 10.1093/gerona/62.7.738

Heckman, 2013, Addressing health care needs for frail seniors in Canada: the role of interRAI instruments, CGS J CME, 3, 8

McIlvennan, 2016, Palliative care in patients with heart failure, BMJ, 353, i1010, 10.1136/bmj.i1010

Doherty, 2016, Carers' needs in advanced heart failure: a systematic narrative review, Eur J Cardiovasc Nurs, 15, 203, 10.1177/1474515115585237

Fendler, 2015, Team-based palliative and end-of-life care for heart failure, Heart Fail Clin, 11, 479, 10.1016/j.hfc.2015.03.010

Whellan, 2014, End-of-life care in patients with heart failure, J Card Fail, 20, 121, 10.1016/j.cardfail.2013.12.003

Lemond, 2011, Palliative care and hospice in advanced heart failure, Prog Cardiovasc Dis, 54, 168, 10.1016/j.pcad.2011.03.012

Chaudhry, 2016, Advanced heart failure: prevalence, natural history, and prognosis, Heart Fail Clin, 12, 323, 10.1016/j.hfc.2016.03.001

Jaarsma, 2009, Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 11, 433, 10.1093/eurjhf/hfp041

McKelvie, 2011, The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care, Can J Cardiol, 27, 319, 10.1016/j.cjca.2011.03.011

Whittingham, 2013, Tools to measure quality of life and carer burden in informal carers of heart failure patients: a narrative review, Palliat Med, 27, 596, 10.1177/0269216313477179

MacIver, 2017, Measuring quality of life in advanced heart failure, Curr Opin Support Palliat Care, 11, 12, 10.1097/SPC.0000000000000250

Rajati, 2016, Comparative evaluation of health-related quality of life questionnaires in patients with heart failure undergoing cardiac rehabilitation: a psychometric study, Arch Phys Med Rehabil, 97, 1953, 10.1016/j.apmr.2016.05.010

Hofer, 2004, The MacNew Heart Disease health-related quality of life instrument: a summary, Health Qual Life Outcomes, 2, 3, 10.1186/1477-7525-2-3

Kelkar, 2016, Utility of patient-reported outcome instruments in heart failure, JACC Heart Fail, 4, 165, 10.1016/j.jchf.2015.10.015

Rector, 1987, Patients' self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire, Heart Fail, 3, 198

Prior, 2015, Variations in patient-reported physical health between cardiac and musculoskeletal diseases: systematic review and meta-analysis of population-based studies, Health Qual Life Outcomes, 13, 71, 10.1186/s12955-015-0265-x

Hui, 2017, The Edmonton Symptom Assessment System 25 years later: past, present and future developments, J Pain Symptom Manage, 53, 630, 10.1016/j.jpainsymman.2016.10.370

Harkness, 2007, Measurement of the caregiving experience in caregivers of persons living with heart failure: a review of current instruments, J Card Fail, 13, 577, 10.1016/j.cardfail.2007.03.013

Makdessi, 2011, The Dutch Objective Burden Inventory: validity and reliability in a Canadian population of caregivers for people with heart failure, Eur J Cardiovasc Nurs, 10, 234, 10.1016/j.ejcnurse.2010.08.006

Elmstahl, 1996, Caregiver's burden of patients 3 years after stroke assessed by a novel caregiver burden scale, Arch Phys Med Rehabil, 77, 177, 10.1016/S0003-9993(96)90164-1

Al-Rawashdeh, 2016, Psychometrics of the Zarit Burden Interview in caregivers of patients with heart failure, J Cardiovasc Nurs, 31, E21, 10.1097/JCN.0000000000000348

Gadoud, 2013, Palliative care for people with heart failure: summary of current evidence and future direction, Palliat Med, 27, 822, 10.1177/0269216313494960

Hochgerner, 2009, Opioids for symptomatic therapy of dyspnoea in patients with advanced chronic heart failure–is there evidence?, Wien Med Wochenschr, 159, 577, 10.1007/s10354-009-0726-0

Lowey, 2013, Short of breath and dying: state of the science on opioid agents for the palliation of refractory dyspnea in older adults, J Gerontol Nurs, 39, 43, 10.3928/00989134-20121204-06

Beattie, 2012, Subcutaneous furosemide in advanced heart failure: has clinical practice run ahead of the evidence base?, BMJ Support Palliat Care, 2, 5, 10.1136/bmjspcare-2011-000199

McClung, 2013, End-of-life care in the treatment of advanced heart failure in the elderly, Cardiol Rev, 21, 9, 10.1097/CRD.0b013e31826d23ea

Ghashghaei, 2016, Palliative care in heart failure, Prog Cardiovasc Dis, 58, 455, 10.1016/j.pcad.2016.01.002

Hauptman, 2006, Chronic inotropic therapy in end-stage heart failure, Am Heart J, 152, 1096.e1, 10.1016/j.ahj.2006.08.003

Simon, 2016, Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults, Cochrane Database Syst Rev, 10, CD007354

Abernethy, 2003, Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea, BMJ, 327, 523, 10.1136/bmj.327.7414.523

Clemens, 2009, Use of oxygen and opioids in the palliation of dyspnoea in hypoxic and non-hypoxic palliative care patients: a prospective study, Support Care Cancer, 17, 367, 10.1007/s00520-008-0479-0

Inglis, 2011, Eur J Heart Fail, 13, 1028, 10.1093/eurjhf/hfr039

Inglis, 2015, Structured telephone support or non-invasive telemonitoring for patients with heart failure, Cochrane Database Syst Rev, CD007228

Clark, 2016, A systematic review of the main mechanisms of heart failure disease management interventions, Heart, 102, 707, 10.1136/heartjnl-2015-308551

Clark, 2014, Determinants of effective heart failure self-care: a systematic review of patients' and caregivers' perceptions, Heart, 100, 716, 10.1136/heartjnl-2013-304852

Riegel, 2009, State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association, Circulation, 120, 1141, 10.1161/CIRCULATIONAHA.109.192628

Fergenbaum, 2015, Care in the home for the management of chronic heart failure: systematic review and cost-effectiveness analysis, J Cardiovasc Nurs, 30, S44, 10.1097/JCN.0000000000000235

Qaddoura, 2015, Efficacy of hospital at home in patients with heart failure: a systematic review and meta-analysis, PLoS One, 10, e0129282, 10.1371/journal.pone.0129282

Wijeysundera, 2013, A population-based study to evaluate the effectiveness of multidisciplinary heart failure clinics and identify important service components, Circ Heart Fail, 6, 68, 10.1161/CIRCHEARTFAILURE.112.971051

Pulignano, 2010, Usefulness of frailty profile for targeting older heart failure patients in disease management programs: a cost-effectiveness, pilot study, J Cardiovasc Med (Hagerstown), 11, 739, 10.2459/JCM.0b013e328339d981

Willey, 2012, Managing heart failure: a critical appraisal of the literature, J Cardiovasc Nurs, 27, 403, 10.1097/JCN.0b013e31822ad3f3

Gomes, 2013, Effectiveness and cost-effectiveness of home palliative care services for adults with advanced illness and their caregivers, Cochrane Database Syst Rev, CD007760

Singer, 2016, Populations and interventions for palliative and end-of-life care: a systematic review, J Palliat Med, 19, 995, 10.1089/jpm.2015.0367

Diop, 2017, Palliative care interventions for patients with heart failure: a systematic review and meta-analysis, J Palliat Med, 20, 84, 10.1089/jpm.2016.0330

Hoffmarcher MM, Oxley H, Rusticelli E. Improved Health System Performance through Better Care Coordination. Health Working Paper No. 30. Paris: OECD Publishing, 2007.

Grone, 2001, Integrated care: a position paper of the WHO European Office for Integrated Health Care Services, Int J Integr Care, 1, e21, 10.5334/ijic.28

Vedel, 2011, Ten years of integrated care: backwards and forwards. The case of the province of Quebec, Canada, Int J Integr Care, 11, e004

Smith, 2009, The Canadian heart health strategy and action plan, Can J Cardiol, 25, 451, 10.1016/S0828-282X(09)70116-3

McDonald, 2007, Vol. 7

Mackie, 2016, Factors enabling implementation of integrated health and social care: a systematic review, Br J Community Nurs, 21, 82, 10.12968/bjcn.2016.21.2.82

Veras, 2014, Integration and continuity of care in health care network models for frail older adults, Rev Saude Publica, 48, 357, 10.1590/S0034-8910.2014048004941

Johri, 2003, International experiments in integrated care for the elderly: a synthesis of the evidence, Int J Geriatr Psychiatry, 18, 222, 10.1002/gps.819

Del Sindaco, 2007, Two-year outcome of a prospective, controlled study of a disease management programme for elderly patients with heart failure, J Cardiovasc Med (Hagerstown), 8, 324, 10.2459/JCM.0b013e32801164cb

Brannstrom, 2014, Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study, Eur J Heart Fail, 16, 1142, 10.1002/ejhf.151

Sidebottom, 2015, Inpatient palliative care for patients with acute heart failure: outcomes from a randomized trial, J Palliat Med, 18, 134, 10.1089/jpm.2014.0192

Ryder, 2011, Multidsciplinary heart failure management and end of life care, Curr Opin Support Palliat Care, 5, 317, 10.1097/SPC.0b013e32834d749e

McKelvie, 2016, Canadian Cardiovascular Society Quality Indicators for Heart Failure, Can J Cardiol, 32, 1038.e5, 10.1016/j.cjca.2015.12.027

Saito, 2016, Meta-analysis of risks for short-term readmission in patients with heart failure, Am J Cardiol, 117, 626, 10.1016/j.amjcard.2015.11.048

Albert, 2016, A systematic review of transitional-care strategies to reduce rehospitalization in patients with heart failure, Heart Lung, 45, 100, 10.1016/j.hrtlng.2015.12.001

Vedel, 2015, Transitional care for patients with congestive heart failure: a systematic review and meta-analysis, Ann Fam Med, 13, 562, 10.1370/afm.1844

Feltner, 2014, Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis, Ann Intern Med, 160, 774, 10.7326/M14-0083

Lambrinou, 2012, Effectiveness of heart failure management programmes with nurse-led discharge planning in reducing re-admissions: a systematic review and meta-analysis, Int J Nurs Stud, 49, 610, 10.1016/j.ijnurstu.2011.11.002

Phillips, 2004, Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis, JAMA, 291, 1358, 10.1001/jama.291.11.1358

Bryant-Lukosius, 2015, The clinical effectiveness and cost-effectiveness of clinical nurse specialist-led hospital to home transitional care: a systematic review, J Eval Clin Pract, 21, 763, 10.1111/jep.12401

Peikes, 2009, Effects of care coordination on hospitalization, quality of care, and health care expenditures among Medicare beneficiaries: 15 randomized trials, JAMA, 301, 603, 10.1001/jama.2009.126

2001

Fishman, 2004, Opportunities and challenges for measuring cost, quality, and clinical effectiveness in health care, Med Care Res Rev, 61, 124S, 10.1177/1077558704267512

Rubin, 2001, The advantages and disadvantages of process-based measures of health care quality, Int J Qual Health Care, 13, 469, 10.1093/intqhc/13.6.469

Mant, 2001, Process versus outcome indicators in the assessment of quality of health care, Int J Qual Health Care, 13, 475, 10.1093/intqhc/13.6.475

Campbell, 2003, Research methods used in developing and applying quality indicators in primary care, BMJ, 326, 816, 10.1136/bmj.326.7393.816

Donabedian, 1988, Quality assessment and assurance: unity of purpose, diversity of means, Inquiry, 25, 173